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Abstract 
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and 
therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are excellent 
candidates for PCa theranostics—they rapidly and efficiently localize in tumor lesions. However, 
high tracer uptake in kidneys and salivary glands are major concerns for therapeutic applications. 
Here, we present the preclinical application of PSMA I&T, a DOTAGA-chelated urea-based PSMA 
inhibitor, for SPECT/CT imaging and radionuclide therapy of PCa. 111In-PSMA I&T showed 
dose-dependent uptake in PSMA-expressing tumors, kidneys, spleen, adrenals, lungs and salivary 
glands. Coadministration of 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) efficiently 
reduced PSMA-mediated renal uptake of 111In-PSMA I&T, with the highest tumor/kidney 
radioactivity ratios being obtained using a dose of 50 nmol 2-PMPA. SPECT/CT clearly visualized 
subcutaneous tumors and sub-millimeter intraperitoneal metastases; however, high renal and 
spleen uptake in control mice (no 2-PMPA) interfered with visualization of metastases in the 
vicinity of those organs. Coadministration of 2-PMPA increased the tumor-to-kidney absorbed 
dose ratio during 177Lu-PSMA I&T radionuclide therapy. Hence, at equivalent absorbed dose to the 
tumor (36 Gy), coinjection of 2-PMPA decreased absorbed dose to the kidneys from 30 Gy to 12 
Gy. Mice injected with 177Lu-PSMA I&T only, showed signs of nephrotoxicity at 3 months after 
therapy, whereas mice injected with 177Lu-PSMA I&T + 2-PMPA did not. These data indicate that 
PSMA I&T is a promising theranostic tool for PCa. PSMA-specific uptake in kidneys can be 
successfully tackled using blocking agents such as 2-PMPA. 
Key words: PSMA; imaging; SPECT; radionuclide therapy; prostate cancer; CRPC; 2-PMPA. 
Introduction 
Prostate cancer (PCa) is a major health problem 
in men. Prognosis is dependent on stage of the disease 
and the five-year survival rate for advanced, 
disseminated PCa is only 29% [1]. Metastatic 
castration-resistant PCa (mCRPC) is associated with 
poor prognosis and diminished quality of life. 
 
Ivyspring  
International Publisher 
 Theranostics 2016, Vol. 6, Issue 6 
 
http://www.thno.org 
850 
Treatment options for mCRPC patients include 
taxane-based therapies (docetaxel, cabazitaxel) and 
novel second-line hormonal therapies (enzalutamide 
and abiterone), all showing moderate survival 
benefits. Unfortunately, those therapies are only 
temporarily effective and development of treatment 
resistance is observed [2, 3]. The bone-seeking 
alpha-emitting radiopharmaceutical Radium-223 
chloride (XofigoTM) has recently been introduced, 
resulting in reduction of bone pain and moderately 
improved survival in mCRPC patients with bone 
metastases [4, 5]. However, the use of this promising 
radiopharmaceutical is limited to the treatment of 
bone metastases. Therefore, there is an urgent need to 
develop more specific therapies that target PCa 
visceral lesions as well.  
Recent developments in PCa-targeted 
radiopharmaceuticals have focused on 
prostate-specific membrane antigen (PSMA) ligands. 
PSMA is a favorable target for imaging and 
radionuclide therapy of PCa, because it is 
overexpressed in 90-100% of local PCa lesions, as well 
as in cancerous lymph node metastases and bone 
lesions. Furthermore, reports indicate that PSMA 
expression levels are further enhanced in high-grade, 
metastatic and castration-resistant PCa [6-9].  
Numerous studies have shown the value of 
radiolabeled PSMA-targeted agents to visualize PCa 
lesions, including PCa metastases [10-18]. Among the 
different PSMA-targeting tracers available, several 
tracers have made their way to the clinic. For PET 
imaging of PCa, Glu-NH-CO-NH-Lys-(Ahx)-68Ga- 
HBED-CC, also known as 68Ga-PSMA-11 or 68Ga- 
PSMA-HBED-CC, is the most commonly used 
compound [14, 18]. Unfortunately, HBED-CC 
(N,N’-bis[2-hydroxy-5-(carboxyethyl)benzyl] ethyle-
nediamine-N,N’-diacetic acid), the chelator used in 
this tracer, is not suitable for radiolabeling with 
radiometals for therapeutic applications (e.g. 177Lu, 
90Y, 213Bi). More recently, a novel 18F-labeled PSMA 
inhibitor, 18F-DCFPyL, was introduced in the clinic 
[19]. For therapy, anti-PSMA monoclonal antibodies 
(J591) radiolabeled with 177Lu and 90Y [11, 20, 21] and 
the small-molecule PSMA inhibitor [131I]MIP-1095 [22] 
have shown promising therapeutic efficacy, although 
with moderate toxicity. Moreover, PSMA ligands with 
DOTA-derived chelators have been developed, which 
can be labeled with diagnostic radionuclides, e.g. 68Ga 
for PET and 111In for SPECT, as well as therapeutic 
radionuclides, e.g. 177Lu, 90Y or 213Bi for radionuclide 
therapy. Such theranostic compounds, i.e. PSMA I&T 
and PSMA-617 (Fig. 1), are of great interest because 
they combine the potential of diagnosis and 
radionuclide therapy using one PSMA targeting 
molecule [23-27].  
 
 
Figure 1. Chemical structures of small-molecule PSMA inhibitors PSMA-11, PSMA-617, and PSMA I&T. 
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Radioligand properties, e.g. lipophilicity, target 
affinity and metabolic stability have been carefully 
optimized for theranostic applications. Monoclonal 
antibodies showed slow blood clearance, which may 
result in myelotoxicity. Small-molecule PSMA 
inhibitors showed the advantage to localize rapidly in 
tumor lesions, including soft-tissue and bone 
metastases. On the other hand, these small inhibitors 
showed high and specific uptake in PSMA-expressing 
kidneys and salivary glands, which is of major 
concern for its application for radionuclide therapy. 
Strategies should therefore be investigated to limit 
radiation-induced damage in healthy organs. Here we 
report on the preclinical application of the 
DOTAGA-chelated urea-based PSMA inhibitor PSMA 
I&T for SPECT/CT imaging and radionuclide therapy 
of PCa. In this study we investigated if coinjection of 
111In-PSMA I&T with 2-(phosphonomethyl)pentane- 
1,5-dioic acid (2-PMPA) could contribute to increasing 
tumor-to-kidney uptake ratio, thereby facilitating 
visualization of metastatic lesions in the vicinity of the 
kidneys, and most importantly reducing toxicity 
during radionuclide therapy. 
Materials and Methods 
Cell culture  
Cell lines were purchased from the American 
Type Culture Collection. The human prostate cancer 
cell line LNCaP was cultured in RPMI 1640 medium 
(GIBCO, BRL Life Sciences Technologies, The 
Netherlands), supplemented with 2 mM glutamine 
(GIBCO) and 10% fetal calf serum (FCS, 
Sigma-Aldrich Chemie BV, The Netherlands) at 37 °C 
in a humidified atmosphere with 5% CO2. LS174T 
colon carcinoma cells were stably transfected with 
human PSMA using the plasmid pcDNA3.1-hPSMA 
and cultured in RPMI 1640 medium supplemented 
with 2 mM glutamine, 10% FCS, and 0.3 mg/ml G418 
[28]. VCaP cells were cultured in RPMI 1640 medium 
containing 10% FCS. PC-346C cells were cultured in 
Dulbecco’s modified Eagle’s F12 medium 
supplemented with 2% FCS, 0.01% BSA 
(Boehringer-Mannheim), 1% 
insulin-transferrin-selenium (Life Technologies), 0.1 
μg/mL fibronectin (Alfa Aesar), 0.1 nM R1881 
androgen, 10 ng/mL epidermal growth factor, 0.5 
μg/mL dexametason, 1 nM triiodothyronine, 0.1 mM 
phosphoethanolamine, 50 ng/mL cholera toxin and 
20 μg/mL fetuin (all from Sigma). 
Radiolabeling 
111In labeling 
PSMA I&T (Fig. 1), a DOTAGA-chelated 
urea-based PSMA inhibitor, was synthetized as 
described previously [25] and kindly provided by the 
Technical University Munich. PSMA I&T was 
radiolabeled with 111InCl3 (Mallinckrodt BV, Petten, 
The Netherlands) in 0.5 M 2-(N-morpholino) 
ethanesulfonic acid (MES) buffer (twice volume of 
111InCl3), pH 5.5, for 10 min at 95 °C under metal-free 
conditions [29]. After incubation, 4 mM 
diethylenetriaminepentaacetic acid (DTPA) was 
added to a final concentration of 0.2 mM to complex 
free 111InCl3. Labeling efficiency was determined by 
instant thin-layer chromatography (ITLC) using silica 
gel coated paper (Agilent Technologies, Palo Alto, 
CA) and 0.1 M ammonium acetate containing 0.1 M 
ethylenediaminetetraacetic acid (EDTA), pH 5.5, as 
the mobile phase. Labeling efficiency exceeded 95% in 
all experiments. 
177Lu labeling 
No-carrier added (n.c.a.) 177LuCl3 was obtained 
from Isotope Technologies Garching (ITG) GmbH 
(Garching, Germany). Labeling was performed in 0.5 
M MES buffer (twice volume of 177LuCl3), pH 5.5, for 
20 min at 95 °C. EDTA was added to a final 
concentration of 5 mM to complex free 177Lu3+ after 
reaction. Labeling efficiency was determined by ITLC 
and radiochemical purity by reverse-phase high 
performance liquid chromatography (RP-HPLC) on 
an Agilent 1200 system (Agilent Technologies). A 
monolithic C18 column (Onyx, 4.6 x 100 mm; 
Phenomenex, Torrance, CA) was used at a flow rate of 
1 ml/min with the following buffer system: buffer A, 
0.1% v/v TFA in water; buffer B, 0.1% v/v TFA in 
acetonitrile; and a gradient of 97% to 0% buffer A 
(5-15 min). The radioactivity of the eluate was 
monitored using an in-line NaI radiodetector (Raytest 
GmbH, Straubenhardt, Germany). Elution profiles 
were analyzed using Gina-star software (version 2.18; 
Raytest GmbH). Labeling efficiency was 95% and 
radiochemical purity was 93-95%. 
Scatchard analysis of PSMA I&T 
Scatchard analysis was performed to determine 
the dissociation constant (Kd) of 111In-PSMA I&T and 
to quantitatively measure PSMA expression on 
LNCaP and LS174T-PSMA cells. Cells were cultured 
to confluence in six-well plates and incubated for 4 h 
on ice with increasing concentrations 111In-PSMA I&T 
(0.03 – 30 nM) in 1 ml RPMI 1640 containing 0.5% w/v 
bovine serum albumin (BSA). Non-specific binding 
was determined by coincubation with 100 µM PSMA 
I&T. After incubation, cells were washed with PBS 
and the cell-associated activity was measured in a 
shielded well-type gamma counter. The specific 
binding (total binding – nonspecific binding) was 
plotted against the bound/free ratio. Data were 
 Theranostics 2016, Vol. 6, Issue 6 
 
http://www.thno.org 
852 
analyzed by linear regression to determine PSMA 
antigen density per cell and to determine the Kd of 
111In-PSMA I&T. 
Autoradiography 
Binding of 111In-PSMA I&T to 10-µm frozen 
sections of patient-derived xenografts (PDXs) and of 
human and mouse kidneys was evaluated using 
autoradiography. Tissue sections were preincubated 
for 5 min in ice-cold binding buffer (5 mM MgCl2, 167 
mM tris(hydroxymethyl)aminomethane hydrochlo-
ride, pH 7.6), followed by incubation for 1 h with 
111In-PSMA I&T (10-9 M) in binding buffer containing 
1% w/v BSA. After incubation, the sections were 
washed successively with ice-cold binding buffer with 
0.25 % w/v BSA for 5 min, binding buffer without 
BSA for 5 min, and ice-cold Ultrapure water for 5 s. 
Dried sections were placed in apposition to phosphor 
screens (PerkinElmer, Super Resolution) for 1 day. 
Radioactivity was assessed using a phosphor imager 
system (Cyclone, Packard, model A431201) and 
quantified using Optiquant software (PerkinElmer, 
Waltham, MA).  
Animal studies 
Animal experiments were performed in male 
BALB/c nude mice (Janvier, le Genest-Saint-Isle, 
France) and were conducted in accordance with the 
principles laid out by the revised Dutch Act on 
Animal Experimentation (1997) and approved by the 
institutional Animal Welfare Committee of the 
Radboud University Nijmegen. At 6-8 weeks of age, 
mice were inoculated subcutaneously with 3 x 106 
LNCaP cells (in RPMI-1640 medium:matrigel 2:1, BD 
Biosciences, Pharmingen) and/or 2.5 x 106 LS174T in 
RPMI-1640 medium. Because LS174T-PSMA 
xenografts showed better tumor take and more 
reproducible growth, the LS174T-PSMA model was 
selected for pharmacokinetic and therapeutic 
experiments. The tracer was injected when tumors 
reached a size of approximately 0.1 cm3. For 
SPECT/CT imaging of intraperitoneal tumors, mice 
were inoculated with 1 x 106 LS174T-PSMA cells in 
RPMI-1640 medium intraperitoneally and imaged 2-3 
weeks after inoculation.  
Dose escalation study 
Four groups of five mice with subcutaneous 
PSMA-expressing xenografts (right flank: LNCaP, left 
flank: LS174T-PSMA) received an intravenous 
injection of 0.2 MBq 111In-PSMA I&T (specific activity 
2 MBq/nmol) in vehicle (PBS/ 0.5% BSA) in the tail 
vein. The effect of the dose of PSMA I&T on the 
biodistribution of 111In-PSMA I&T was studied by 
administering different doses (0.1 – 0.3 – 1 – 10 
nmol/mouse) to groups of five mice. Two hours post 
injection, mice were euthanized using 
CO2/O2-asphyxiation and the biodistribution of 
111In-PSMA I&T was determined ex vivo. Tumors, 
blood, and relevant organs and tissues were dissected, 
weighed, and radioactivity in each sample was 
quantified using a γ-counter. The results were 
expressed as percentage of injected dose per gram of 
tissue (%ID/g). 
Reduction of renal tracer uptake with 2-PMPA 
Five groups of five mice with subcutaneous 
LS174T-PSMA and LNCaP xenografts received an 
intravenous injection of 0.2 MBq 111In-PSMA I&T (0.3 
nmol) in vehicle in the tail vein. Mice were injected 
with either 111In-PSMA I&T alone or in combination 
with 2-PMPA (10, 20, 50 nmol) to reduce specific 
binding in kidneys. One additional group was 
injected with 4 mg gelofusine 6 min before injection of 
111In-PSMA I&T to investigate tubular reabsorption 
mediated renal uptake. Two hours after injection, 
mice were euthanized and the biodistribution was 
determined ex vivo.  
To determine the best time point of 2-PMPA 
injection, five groups of five mice with subcutaneous 
LS174T-PSMA xenografts received an intravenous 
injection of 0.2 MBq 111In-PSMA I&T (0.3 nmol) with a 
preinjection (15 or 60 min), a coinjection, or a 
postinjection (15 or 60 min) of 50 nmol of 2-PMPA. 
Two hours after injection, mice were euthanized and 
the biodistribution was determined ex vivo. 
Pharmacokinetics 
To determine the pharmacokinetics of 
111In-PSMA I&T, eight groups of four mice with 
subcutaneous LS174T-PSMA xenografts received an 
intravenous injection of 0.2 MBq 111In-PSMA I&T (0.3 
nmol) in vehicle followed by ex vivo biodistribution at 
1, 4, 24, and 48 h after injection. Mice were injected 
with or without 2-PMPA (50 nmol) coinjection to 
study the effect of 2-PMPA on tumor and kidney 
retention of 111In-PSMA I&T. 
SPECT/CT imaging 
Mice with subcutaneous (n = 4) or 
intraperitoneal (n = 12) LS174T-PSMA tumors were 
injected intravenously with 20 MBq 111In-PSMA I&T 
(0.3 nmol, specific activity 67 MBq/nmol) in vehicle, 
with or without coinjection of 2-PMPA (50 nmol). One 
hour after injection, mice were euthanized by CO2/O2 
asphyxation and images were acquired with the 
U-SPECT-II/CT (MILabs, Utrecht, The Netherlands) 
[30]. Mice were scanned for 50 min using the 1.0 mm 
diameter pinhole mouse high sensitivity collimator 
tube, followed by a CT scan (spatial resolution 160 
µm, 65 kV, 615 µA) for anatomical reference. Scans 
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were reconstructed with MILabs reconstruction 
software, using an ordered-subset expectation 
maximization algorithm, energy window 154 – 188 
kEv, 3 iterations, 16 subsets, voxel size of 0.2 mm, and 
Gaussian filter 0.4 mm. SPECT/CT scans were 
analyzed and maximum intensity projections (MIPs) 
were created using the Inveon Research Workplace 
software (IRW, version 4.1).  
Dosimetry 
Biodistribution data obtained in the 
pharmacokinetic study were used to estimate the 
absorbed radiation doses to the organs and tumor. A 
single-exponential expression was fitted to the 
activity data at 1, 4, 24 and 48 h, and the cumulative 
activity concentration in each organ was calculated by 
analytic integration of the fitted expression.  
Absorbed doses to the organs were calculated 
according to the MIRD-scheme [31] with the 
following equation: 𝐷𝐷(𝑟𝑟𝑇𝑇) = ∑ Ã(𝑟𝑟𝑆𝑆) × 𝑆𝑆(𝑟𝑟𝑇𝑇 ← 𝑟𝑟𝑆𝑆)𝑟𝑟𝑆𝑆 , 
with D(rT) the absorbed dose to a target organ rT, Ã(𝑟𝑟𝑆𝑆) 
the time-integrated activity in a source organ  rS and 
S(rT ← rS) the absorbed dose rate per unit activity of 
177Lu. The S-values were obtained for a standardized 
25 g mouse from the RADAR realistic animal models 
[32]. The biodistribution data were measured in 
activity concentration and hence the time-integrated 
activity concentration was obtained and this was 
multiplied with the source organ mass, as used in the 
phantom for the S-value calculation. The dosimetry 
calculations assume comparable biodistribution of 
111In-PSMA I&T and 177Lu-PSMA I&T. Absorbed 
doses to renal cortex were estimated assuming 
localization of 177Lu-PSMA I&T in the cortex [33]. 
Radionuclide therapy 
To assess potential renal toxicity of 177Lu-PSMA 
I&T, three groups of four mice with subcutaneous 
LS174T-PSMA xenografts were injected intravenously 
with 100 MBq 177Lu-PSMA I&T (0.35 nmol) in vehicle 
with or without 2-PMPA (50 nmol) coinjection, or 
with vehicle (PBS/ 0.5% BSA). Body weight was 
monitored twice weekly. Renal function was assessed 
three months after treatment by quantification of 
renal uptake of 99mTc-dimercaptosuccinic acid 
(99mTc-DMSA) using SPECT [34] and by measuring 
plasma creatinine levels. DMSA (Renocis, IBA 
Molecular, The Netherlands) was radiolabeled with 
99mTcO4-, which was eluated from a 
99Mo/99mTc-generator (GE Healthcare, The 
Netherlands). Mice were injected with 29 ± 5 MBq 
99mTc-DMSA and images were acquired with the 
U-SPECT-II/CT, 2 h post injection, 20 min acquisition, 
scan range of 2.6 x 2.6 x 5.2 cm, using the 1.0 mm 
diameter pinhole mouse high sensitivity collimator 
tube. Scans were reconstructed with MILabs 
reconstruction software, using an ordered-subset 
expectation maximization algorithm, energy window 
126-154 kEv, 3 iterations, 16 subsets, voxel size of 0.2 
mm, and Gaussian filter 0.4 mm. Standards 
containing 99mTc-DMSA (0.036-3.36 MBq) were 
scanned using the same scanning protocol and a 
standard curve was derived for quantification. Scans 
were quantified by drawing a volume of interest 
(VOI) around the kidneys using the IRW software. 
Four days prior to scanning, plasma samples were 
collected and creatinine levels were analyzed by 
Aeroset (Abbott Diagnostics). Endpoint criteria were 
defined as body weight loss of > 20% of the initial 
body weight or body weight loss of > 15% within two 
days. One mouse reached a humane endpoint 
criterion 111 days after the start of therapy. The other 
mice were euthanized 118 days after the start of 
therapy for histopathological analysis of the kidneys. 
Two-µm sections of paraffin-embedded kidneys were 
stained with periodic acid Schiff following routine 
diagnostic procedures and analyzed for 
morphological alterations by an experienced 
pathologist (MC). 
To determine the therapeutic efficacy of 
177Lu-PSMA I&T, three groups of ten mice with 
subcutaneous LS174T-PSMA xenografts were injected 
intraveneously with 100 MBq 177Lu-PSMA I&T (0.35 
nmol) in vehicle with or without 2-PMPA (50 nmol) 
coinjection, or with vehicle (PBS/ 0.5% BSA). Tumor 
growth was monitored by caliper measurements in 
three dimensions twice weekly. Body weight was 
monitored twice weekly. Endpoint criteria were 
defined as (1) body weight loss of > 20% of the initial 
body weight or body weight loss of > 15% within two 
days, (2) tumor volume of 2000 mm3, (3) ulceration of 
the tumor. 
Statistical analysis 
Statistical analyses were performed using PASW 
Statistics version 18.0 (Chicago, IL) and GraphPad 
Prism version 5.03 (San Diego, CA). Differences in 
uptake of 111In-PSMA I&T were tested for significance 
using the nonparametric Kruskal-Wallis and 
Mann-Whitney U test. Survival was described with 
the median survival, and survival curves were 
compared with the log-rank test. A p-value below 0.05 
was considered significant. 
Results 
111In-PSMA I&T shows high specificity to 
PSMA-expressing PCa cells, PCa xenografts, 
and kidneys in vitro 
Binding of 111In-PSMA I&T was assessed in vitro 
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on LNCaP and LS174T-PSMA cells in saturation 
binding experiments. The equilibrium binding 
constant (Kd) of 111In-PSMA I&T was 3.9 ± 1.2 nM for 
LNCaP and 5.6 ± 1.2 nM for LS174T-PSMA. The 
number of 111In-PSMA I&T binding sites was 137,000 
± 13,000 sites/cell for LNCaP and 43,000 ± 6,000 
sites/cell for LS174T-PSMA. 
Binding of 111In-PSMA I&T was also evaluated 
on frozen xenograft tumors and kidney sections using 
autoradiography as shown in Fig. 2. 111In-PSMA I&T 
showed high binding to all PSMA-expressing 
xenograft sections (LNCaP, PC310, PC346c, PC295 
and PC82) and PSMA-expressing kidneys (mouse and 
human). Binding to LNCaP tumors was 6 times 
higher than binding to human kidneys and binding to 
mouse kidney was 2 times higher than binding to 
human kidneys. Binding to tumors showing no or 
very low expression of PSMA (PC3, VCaP, PC133, 
PC339, PC324) was very low, showing the 
target-specificity of the tracer. 
 
 
Figure 2. Specificity of 111In-PSMA I&T for detecting PSMA-expressing 
tumors and tissues. High binding was observed on PSMA-expressing tumor 
sections (LNCaP, PC310, PC346c, PC295 and PC82) and PSMA-expressing kidneys 
(mouse and human), whereas no binding was observed to tumors showing no or very 
low expression of PSMA (PC3, VCaP, PC133, PC339, PC324). 
 
111In-PSMA I&T specifically accumulates in 
PSMA-expressing human xenografts in mice 
The optimal tumor targeting doses of 
111In-PSMA I&T were 0.1 – 0.3 nmol for LS174T-PSMA 
tumors and 0.1 – 1.0 nmol for LNCaP tumors (Fig. 
3A). Tumor uptake with 0.3 nmol 111In-PSMA I&T 
was 17.0 ± 2.4 %ID/g and 11.7 ± 5.5 %ID/g for 
LS174T-PSMA and LNCaP, respectively (p = 0.095). 
Tumor uptake was significantly reduced from 0.3 
nmol to 1 nmol tracer (p = 0.008) and from1 nmol to 10 
nmol tracer (p = 0.008) for LS174T-PSMA and LNCaP, 
respectively. The tracer also specifically accumulated 
in kidneys, spleen, lungs, salivary glands, and 
adrenals. The highest uptake was measured in 
kidneys (122 ± 27.0 %ID/g for 0.3 nmol 111In-PSMA 
I&T).  
Coinjection of 2-PMPA significantly reduces 
renal uptake of 111In-PSMA I&T  
To reduce renal retention, different kidney 
protecting strategies were evaluated (Fig. 3B). 
Coinjection of 4 mg gelofusine did not significantly 
reduce renal uptake of 111In-PSMA I&T (p = 0.42), 
whereas coinjection of 10 nmol 2-PMPA significantly 
reduced uptake in kidneys (p = 0.008), spleen (p = 
0.016), lung (p = 0.032), adrenals (p = 0.032), and 
LS174T-PSMA tumors (p = 0.008), but not in LNCaP 
tumors (p = 0.310). The highest tumor-to-kidney ratios 
for LS174T-PSMA were obtained with 50 nmol 
2-PMPA. Coinjection of 50 nmol 2-PMPA resulted in a 
7-fold reduction in renal uptake (from 135.9 ± 31.2 
%ID/g to 19.5 ± 1.8 %ID/g), whereas tumor uptake 
was only reduced 2-fold: from 14.9 ± 2.8 %ID/g to 6.8 
± 1.0 %ID/g (LS174T-PSMA) and from 11.0 ± 6.0 
%ID/g to 5.4 ± 2.3 %ID/g (LNCaP). Timing of 
2-PMPA injection significantly influenced the 
tumor/kidney tracer uptake ratios (p<0.001). Most 
effective renal tracer uptake reduction was obtained 
by coinjection of 111In-PSMA I&T with 2-PMPA or 
preinjection of 2-PMPA 15 min before 111In-PSMA 
I&T. Kidney/tumor tracer uptake ratio was 
significantly higher after coinjection as compared to 
15 min preinjection (p = 0.008) of 2-PMPA (Fig. 3C).  
Coinjection of 2-PMPA improves the 
tumor-to-kidney absorbed dose ratio 
The optimal 111In-PSMA I&T tracer dose (0.3 
nmol) was selected to determine the tracer 
pharmacokinetics. Biodistribution studies were 
performed with and without 2-PMPA (coinjection of 
50 nmol) for renal protection. For 111In-PSMA I&T 
alone, uptake in tumor was the highest at 1 and 4 h 
after injection, and significantly decreased between 4 
and 24 h after injection (p = 0.029) (Fig. 4A). For 
111In-PSMA I&T with 2-PMPA coinjection, tumor 
uptake was the highest at 1 h after injection and 
significantly decreased from 1 to 4 h after injection 
already (p = 0.029) (Fig. 4B). Uptake in 
PSMA-expressing healthy organs significantly 
decreased for both groups between 4 and 24 h after 
injection (p = 0.029). 
Single-exponential curves were fitted to the 
biodistribution data and estimated absorbed doses to 
tumor and organs were calculated (Fig. 4C). 
Estimated absorbed doses from 100 MBq 177Lu-PSMA 
I&T in tumor, kidneys, spleen, and adrenals were 36, 
30, 1, and 2 Gy, respectively, for 177Lu-PSMA I&T 
alone and 15, 5, 0.2, and 0.3 Gy, respectively, for 
177Lu-PSMA I&T with 2-PMPA. Tumor-to-kidney 
 Theranostics 2016, Vol. 6, Issue 6 
 
http://www.thno.org 
855 
dose ratio was substantially improved from 1.2 to 3.0 
when 177Lu-PSMA I&T was coinjected with 2-PMPA. 
Consequently, at an equivalent absorbed dose to the 
tumor (36 Gy), coinjection of 2-PMPA decreases 
absorbed dose to the kidneys from 30 Gy to 12 Gy. 
These absorbed doses to kidneys were calculated 
assuming uniform distribution of radioactivity. 
However, SPECT scans obtained 1 h after injection of 
177Lu-PSMA I&T clearly showed preferential 
localization of radioactivity in the renal cortex (Fig. 
S1). Therefore, dosimetric calculations were adjusted 
to estimate absorbed doses to renal cortex, taking into 
account this preferential localization of 177Lu-PSMA 
I&T in the cortex. Absorbed doses to renal cortex were 
44 and 7.3 Gy for 177Lu-PSMA I&T alone and 
177Lu-PSMA I&T with 2-PMPA, respectively. 
Absorbed doses to other organs from 100 MBq of 
177Lu-PSMA I&T were below 1 Gy. 
 
Figure 3. Biodistribution of 111In-PSMA I&T in mice bearing LS174T-PSMA and LNCaP xenografts. Dose optimization (A), effect of 2-PMPA coinjection (10-50 
nmol) or preinjection of gelofusine (B), and time schedule optimization of 2-PMPA injection (C) are depicted. 
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Figure 4. Pharmacokinetics and dosimetry of 111In-PSMA I&T in mice 
bearing LS174T-PSMA xenografts. Biodistribution of 111In-PSMA I&T (0.3 nmol) 
alone (A) or with coinjection of 50 nmol 2-PMPA (B) at different time points after 
injection. Absorbed doses (in Gy/100 MBq 177Lu-PSMA I&T) were extrapolated from 
biodistribution data with and without 2-PMPA coinjection (C). 
 
Coinjection of 2-PMPA improves visualization 
of metastatic tumor lesions located near 
kidneys and spleen  
SPECT/CT imaging with 111In-PSMA I&T, with 
or without 2-PMPA, clearly visualized 
subcutaneously growing LS174T-PSMA tumors and 
intraperitoneally growing LS174T-PSM metastases, 
whereas no uptake was observed in PSMA-negative 
LS174T tumors (Fig. 5A). High renal and spleen tracer 
uptake was observed in mice that did not receive 
coinjection of 2-PMPA, which interfered with 
visualization of metastases growing in the vicinity of 
these organs (Fig. 5B). 
Coinjection of 2-PMPA protects from 
nephrotoxicity during 177Lu-PSMA I&T 
radionuclide therapy 
Non-tumor bearing mice treated with vehicle or 
177Lu-PSMA I&T + 2-PMPA gained body weight over 
110 days (Fig. 6A). In contrast, an increase in body 
weight was observed up to 50 days for mice treated 
with 177Lu-PSMA I&T only, followed by a slow 
decline in body weight up to 110 days. Three months 
after therapy, renal function was monitored by 
measuring renal uptake of 99mTc-DMSA and plasma 
creatinine levels. Renal uptake of 99mTc-DMSA was 
significantly reduced in mice treated with 
177Lu-PSMA I&T (1.0 ± 0.3 %ID/g) as compared to 
mice treated with vehicle (10.5 ± 1.0 %ID/g, p<0.001) 
or 177Lu-PSMA I&T + 2-PMPA (9.8 ± 1.6 %ID/g, 
p<0.001) (Fig. 6B and 6C). Plasma creatinine levels 
were increased in mice treated with 177Lu-PSMA I&T 
(8.2 ± 1.7 %ID/g) as compared to mice treated with 
vehicle (4.2 ± 1.6 %ID/g, p = 0.029) or 177Lu-PSMA 
I&T + 2-PMPA (4.7 ± 2.1 %ID/g, p = 0.114) (Fig. 6D). 
Kidneys of mice treated with 177Lu-PSMA I&T + 
2-PMPA or vehicle showed normal morphology, 
whereas kidneys of mice treated with 177Lu-PSMA 
I&T showed extensive cortical damage (Fig. 6E). 
Glomerular damage was denoted by segmental 
glomerular basement membrane thickening and 
wrinkling, and mesangial matrix increase, with 
pyknotic endothelial cells and podocytes. In addition, 
there was focal, global glomerular sclerosis. The 
tubular interstitial compartment of the cortex showed 
extreme acute tubular necrosis with atypia of the 
epithelial cells. 
Therapeutic efficacy of 177Lu-PSMA I&T is 
influenced by 2-PMPA 
LS174T-PSMA tumor growth was significantly 
inhibited by 100 MBq of 177Lu-PSMA I&T. A more 
effective growth inhibition was observed with 
177Lu-PSMA I&T alone as compared to 177Lu-PSMA 
I&T + 2-PMPA. Mean doubling time for tumors of 
mice treated with vehicle, 177Lu-PSMA, and 
177Lu-PSMPA + 2-PMPA were 6.1 ± 1.1 days, 13.9 ± 1.7 
days, and 7.3 ± 1.7 days, respectively (Fig. 7A). 
Median survival for these groups was 13 days, 29 
days, and 19 days, respectively (p<0.0001, Fig. 7B). 
Median survival significantly decreased in the group 
that received 2-PMPA in comparison with 
177Lu-PSMA I&T alone (p = 0.0007). 
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Discussion 
A theranostic approach for detection, staging, 
treatment, and follow-up of PCa would be highly 
valuable to achieve personalized PCa treatment. 
PSMA is a very interesting target for such a 
theranostic approach, due to its consistent 
overexpression on PCa at all stages of disease. In 
recent years the number of PSMA-targeted agents for 
diagnostics and therapeutic applications has 
increased tremendously [35]. Currently, two 
theranostic PSMA-ligands are being evaluated in the 
clinic, namely PSMA I&T [25-27] and PSMA-617 [23, 
36-38]. These 2 compounds contain an identical 
urea-binding motif, but have a different linker and 
chelator (Fig. 1). PSMA I&T contains a DOTAGA 
chelator, whereas PSMA-617 contains a DOTA 
chelator. The DOTAGA chelator and the presence of a 
3-iodo-D-tyrosine in the linker of PSMA I&T have 
shown a favorable effect on the binding properties of 
urea-based small-molecule PSMA inhibitors [24, 25]. 
PSMA I&T and PSMA-617 have been shown to 
efficiently detect PCa lesions with high contrast, but 
also display very high uptake in kidneys and salivary 
glands, which raises concerns regarding potential 
toxicity during radionuclide therapy. Preliminary 
results of 177Lu-PSMA-617 therapy in patients showed 
no acute renal insufficiencies in 2 months follow-up 
time, but longer follow-up is needed to get more 
insight into late-stage renal toxicity [36]. Similarly, no 
evidence of renal insufficiencies was reported for 
patients treated with 177Lu-PSMA I&T over a 
follow-up period of at least 6 months [39]. In this 
study, 56 patients with progressive mCRPC received 
1-5 cycles of 177Lu-PSMA I&T, with a median 
administered activity per cycle of 5.76 GBq (3.6-8.7 
GBq), and no significant change in serum creatinine 
level was observed after therapy. 
Our study aimed to investigate the impact of 
healthy tissue uptake on the theranostic potential of 
PSMA I&T for SPECT imaging and radionuclide 
therapy of PCa. Our data showed that 111In-PSMA 
I&T accumulated in PSMA-positive tumors, but not in 
PSMA negative tumors. In addition, PSMA-mediated 
uptake was observed in several normal murine 
tissues, including kidneys, spleen, salivary glands, 
adrenals, and lungs, of which kidneys showed the 
highest uptake. Our biodistribution data of 
111In-PSMA I&T were consistent with previously 
published data for 177Lu-PSMA I&T [25]. Moreover, 
we show that uptake of 111In-PSMA I&T in 
PSMA-expressing tissues can be blocked by 
coinjection of 2-PMPA in a dose-dependent manner, 
with the highest effect being obtained in the kidneys. 
Coadministration of 2-PMPA significantly reduced 
tumor uptake as well, but to a lower extent than 
kidney uptake, resulting in increased 
tumor-to-kidney ratios at all doses tested. Hillier et al. 
have shown that coinjection of 50 mg/kg 2-PMPA, a 
phosphonate-based PSMA inhibitor, nearly 
completely blocked tumor and kidney uptake of the 
PSMA inhibitor [123I]MIP1095 [40]. More recently, 
Kratochwil et al. have shown the potential of 2-PMPA 
to selectively block kidney uptake without reducing 
tumor uptake by injecting 2-PMPA (0.2 – 50 mg/kg) 1 
or 16 hours after injection of the PSMA inhibitors 
99mTc-MIP1404 and 125I-MIP1095, respectively [41]. 
They reported rapid and efficient displacement of 
renal tracer uptake with minimal effects on tumor 
uptake and suggested that a higher internalization 
rate by tumor cells in comparison with renal cells 
could explain these differential effects on tumor and 
kidneys.  
 
Figure 5. SPECT/CT imaging of 
111In-PSMA I&T in PSMA-expressing 
xenografts. (A) Representative SPECT/CT 
images of subcutaneous LS174T-PSMA 
xenografts (right shoulder) and LS174T (left 
shoulder) 1 h after injection of 111In-PSMA I&T 
(0.3 nmol, 20 MBq) without (left) or with (right) 
coinjection of 50 nmol 2-PMPA. (B) 
Representative SPECT/CT images of 
intraperitoneal metastatic lesions of 
LS174T-PSMA cells 1 h after injection of 
111In-PSMA I&T (0.3 nmol, 20 MBq) without 
(left) or with (right) coinjection of 50 nmol 
2-PMPA. Metastatic lesions were located 
around intestines, spleen and pancreas. High 
signal intensity in kidneys and spleen interfered 
with visualization of metastases in this area 
when 2-PMPA was not administered. 
 
 Theranostics 2016, Vol. 6, Issue 6 
 
http://www.thno.org 
858 
 
Figure 6. Toxicity of 177Lu-PSMA I&T in non-tumor bearing mice. Mice (n = 4 per group) were treated with 177Lu-PSMA I&T (100 MBq, 0.35 nmol) with or without 
2-PMPA (50 nmol) on day 0. Control mice were injected with vehicle. Body weight follow-up (A), quantification of 99mTc-DMSA uptake (B), 99mTc-DMSA SPECT/CT scans (C), 
plasma creatinine levels (D), and periodic acid Schiff stained kidneys from treated mice (E) are displayed. Body weight loss, decreased renal uptake of 99mTc-DMSA, and increased 
plasma creatinine levels are observed for the group treated with 177Lu-PSMA I&T without 2-PMPA. Kidneys of mice treated with 177Lu-PSMA I&T + 2-PMPA or vehicle show 
normal morphology, whereas kidneys of mice treated with 177Lu-PSMA I&T show extensive cortical damage. Tubular damage can be visualized by loss of epithelial cells and atypia 
of the remaining cells (10 X image). In addition, glomerular damage can be visualized by endothelial cell and podocyte pyknosis, focal glomerular basement membrane wrinkling 
and mesangial matrix increase (40 X image). 
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Figure 7. Therapeutic efficacy of 177Lu-PSMA I&T in LS174T-PSMA 
tumors. Mice (n = 8 per group) were treated with 177Lu-PSMA I&T (100 MBq, 0.35 
nmol), with or without coinjection of 2-PMPA (50 nmol) on day 0. Control mice were 
injected with vehicle. Kaplan-Meier survival curves (A) and tumor size follow-up (B) 
are displayed. 
 
In contrast with data obtained by Kratochwil et 
al. for 125I-MIP1095 and 99mTc-MIP1404, injection of 
2-PMPA (50 nmol per 25 g mouse ~ 0.45 mg/kg) 1 
hour after injection of 111In-PSMA I&T did not reduce 
renal uptake. In our study, only coinjection or 15 min 
preinjection resulted in effective inhibition of 
111In-PSMA I&T renal uptake. This resulted in a 7-fold 
reduction in renal uptake at 2 h after injection, 
whereas tumor uptake was reduced only by a factor 
of two. The differential effect on tumor and kidneys 
might be explained by differences in the kinetics of 
tumor and renal uptake of 2-PMPA and PSMA I&T. 
Because of its small size (Mw = 226 g/mol), high 
hydrophilicity, and low tissue penetration [42], 
2-PMPA might be cleared rapidly from the 
circulation, resulting in higher accumulation in 
kidneys than in tumor. Additional studies are needed 
to determine the kinetics of 2-PMPA uptake in tumor 
and kidneys, providing more insight into this 
mechanism and facilitating optimization of 2-PMPA 
injection schedule in patients. Pre- or coinjection of 
blocking agents is preferred over postinjection, 
because the kidneys will be protected from 
radiation-induced damage from the start of therapy, 
which could be especially beneficial with short 
half-life radionuclides, e.g. 213Bi. 
In the case of application of PSMA inhibitors for 
PET imaging, high uptake observed in kidneys and 
salivary glands is not of major concern for detection of 
primary tumors or distant metastases. However, if 
metastases are situated in the vicinity of organs 
showing tracer uptake, this could interfere with the 
interpretation of the images. Our metastatic model 
indicates that coinjection of 111In-PSMA I&T with 
2-PMPA improved the visualization of intraperitoneal 
tumor lesions in the vicinity of kidneys, adrenals, and 
spleen.  
For PSMA-targeted radionuclide therapy, high 
uptake observed in kidneys and salivary glands are 
major concerns. To investigate the potential protective 
effect of 2-PMPA on renal toxicity, a therapeutic study 
was performed with 100 MBq 177Lu-PSMA I&T with 
and without coinjection of 2-PMPA. Several groups 
have reported radiation-induced nephropathy in mice 
between 15 and 30 weeks after therapy using 
177Lu-labeled therapeutic agents, translating into 
reduced 99mTc-DMSA clearance and increased serum 
creatinine levels [33, 43, 44]. Svensson et al. have 
reported a threshold dose value of 24 Gy to renal 
cortex for 177Lu-DOTATATE in nude mice [33]. In our 
study, estimated absorbed doses to renal cortex were 
44 Gy and 7.3 Gy, for 177Lu-PSMA I&T and 
177Lu-PSMA I&T + 2-PMPA, respectively. 
Consistently, nephrotoxicity was observed in mice 
treated with 100 MBq 177Lu-PSMA I&T at 3 months 
after start of therapy, as shown by the decreased 
99mTc-DMSA uptake and increased serum creatinine 
levels. On the contrary, nephrotoxicity was not 
observed when 2-PMPA was coadministered.  
Therapeutic efficacy of 177Lu-PSMA I&T was 
significantly reduced by coinjection of 2-PMPA, 
which can be explained by the 2-fold higher dose 
delivered to the tumor cells for 177Lu-PSMA I&T alone 
in comparison with 177Lu-PSMA I&T with 2-PMPA. 
To improve therapeutic efficacy, the dose delivered to 
the tumor for 177Lu-PSMA I&T with 2-PMPA could be 
increased by administering a double dose of 
177Lu-PSMA I&T. This would result in an estimated 
absorbed dose of 30 Gy to the tumor and 14.6 Gy to 
the renal cortex, provided that receptor saturation has 
not been reached. Alternatively, 2 doses of 
177Lu-PSMA I&T could be administered at an interval 
allowing clearance of the tracer. 
These preclinical results illustrate the potential of 
PSMA I&T for theranostic approaches in PCa. 
However, the extrapolation of these data to the 
clinical situation should be performed carefully. 
Pitfalls might include differences in expression of 
PSMA in human and its murine homolog Folh1 in 
mice, differences in affinities for PSMA expressed on 
human (xenograft) tumors and Folh1 expressed on 
murine tissues, and differences in pharmacokinetics 
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in mice and humans. Due to differences in expression 
pattern of Folh1 in mouse organs and PSMA in 
human organs, further studies should be performed 
in patients to determine the effect of 2-PMPA blocking 
on normal organs showing high PSMA expression, 
such as the salivary glands and kidneys. Even though 
no evidence of nephrotoxicity was observed in the 
first studies with high doses of 177Lu-PSMA I&T in 
patients, further investigations to reduce the dose to 
kidneys and salivary glands in patients might 
enhance the maximum tolerable dose and improve 
the therapeutic window. 
Moreover, safety and pharmacokinetics of 
2-PMPA should be tested in patients. In preclinical 
models, PSMA inhibitors have shown utility for 
treatment of neurological diseases in which excessive 
excitatory glutamate transmission is pathogenic [45]. 
Indeed, PSMA inhibition could limit detrimental 
excess glutamate release in the nervous system, by 
blocking conversion of N-acetylaspartylglutamate 
into glutamate. Importantly, PSMA inhibition had no 
effect on basal glutamate transmission in healthy 
animals [46]. Even though 2-PMPA has shown high 
affinity and selectivity towards PSMA, it was not 
evaluated in patients because of its poor oral 
bioavailability and limited brain penetration. A more 
lipophilic PSMA inhibitor, 2-(-3-mercaptopropyl) 
pentanedioic acid, which is almost as potent as 
2-PMPA, was found to be safe and well tolerated in 
healthy subjects [47]. For our application, however, 
the use of a hydrophilic PSMA inhibitor with poor 
brain penetration would be preferred, because it 
would less likely induce adverse events. In 
conclusion, future research is warranted to address 
the identified pitfalls and translate this concept in PCa 
patients. 
In conclusion, PSMA I&T is a highly promising 
theranostic agent for radionuclide imaging and 
therapy of PCa. Coinjection of 2-PMPA efficiently 
reduced renal uptake, thereby improving 
visualization of intraperitoneal tumor lesions in the 
vicinity of kidneys, adrenals, and spleen and 
protecting from nephrotoxicity after radionuclide 
therapy. Because 2-PMPA also reduced tumor uptake, 
it might hamper therapeutic efficacy, which could be 
resolved by increasing amounts of injected activity. 
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